The coprescription of contraindicated drugs with statins: Continuing potential for increased risk of adverse events

American Journal of Therapeutics

Volumn 14, Issue 1, 2007, Pages 30-40

  Stang, Paul ^a,b   Morris, Lisa ^c   Kempf, Judy ^d   Henderson, Scott ^c   Yood, Marianne Ulcickas ^a   Oliveria, Susan ^a  

^a Galt Associates Inc   (United States)

^b WEST CHESTER UNIVERSITY   (United States)

^c IQVIA   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Coprescribing; HMG CoA reductase inhibitors; Myopathy; Package insert; Rhabdomyolysis; Statins

Indexed keywords

AMPRENAVIR; ANTIFUNGAL AGENT; ATORVASTATIN; AZITHROMYCIN; CLARITHROMYCIN; CLOFIBRATE; CYCLOSPORIN A; DIRITHROMYCIN; ERYTHROMYCIN; ERYTHROMYCIN ETHYLSUCCINATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUCONAZOLE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LOPINAVIR PLUS RITONAVIR; MACROLIDE; MEVINOLIN; NEFAZODONE; NELFINAVIR; NICOTINAMIDE; NICOTINIC ACID; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SIMVASTATIN; TROLEANDOMYCIN; UNINDEXED DRUG; VERAPAMIL; VORICONAZOLE; WARFARIN;

ARTICLE; ATTRIBUTABLE RISK; BLEEDING; COMPARATIVE STUDY; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG LABELING; DRUG SAFETY; FREQUENCY ANALYSIS; HEALTH CARE PERSONNEL; HUMAN; INTERVENTION STUDY; MYOPATHY; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES;

COHORT STUDIES; DRUG INTERACTIONS; DRUG UTILIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSURANCE CLAIM REVIEW; PHARMACEUTICAL PREPARATIONS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; RISK;

EID: 33847115366     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000208875.61480.c8     Document Type: Article

References (29)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study. N Engl J Med. 1995;333:1301-1307.
3. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25-60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995;15:678-682.
4. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmoL/liter (200 to 300 mg/dL) plus two additional atherosclerotic risk factors. J Am Coll Cardiol. 1993;72: 1031-1037.
5. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151:43-49.
6. Herbert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke and total mortality: an overview of randomized trials. JAMA. 1997;278:1301-1307.
7. National Prescription Audit. IMS Health; 2002.
8. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methyl coenzyme A reductase inhibitors: are the statins mechanistically similar? Pharmacol Ther. 1998;80:1-34.
9. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences. Clin Pharmacokinet. 1997;32:403-425.
10. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-418.
11. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother. 2001;35:908-17.
12. Adkins JC, Faulds D. Micronized fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidemia. Drugs. 1997;54:615-633.
13. Wacholder S. Binomial regression in GLIM: estimating risk ratios and risk differences. Am J Epidemiol. 1986;123:174-184.
14. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett. 2002;128:159-168.
15. Gaist D, Garcia-Rodriguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology. 2001;12:565-569.
16. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscles: are all statins the same? Drug Safety. 2002; 25:649-663 (citing UK MediPlus data obtained from the UK Medicines Control Agency Feb 2002 update; Table III, p 657).
17. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother. 2001;35:908-917.
18. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36:288-295.
19. Tolbert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol. 1988;62:28J-34J.
20. Smith CC, Bernstein LI, Davis RB, et al. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med. 2003;163:688-692.
21. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA. 2000;284:3036-3039.
22. Schiff GD, Keehr LM, Sai TT, et al. High rates of adverse effects and patient unawareness of withdrawn lipid-lowering drug combination in a public hospital clinic. Pharmacoepidemiology and Drug Safety. 2002;11:643-645.
23. Fedder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on size, sex, and age distribution of the treatment-eligible population. Circulation. 2002:105:152-156.
24. Jackevicius CA, Anderson GM, Leiter L, et al. Use of the statins in patients after acute myocardial infarction: does evidence change practice? Arch Intern Med. 2001;161:183-188.
25. McBride P, Schrott H, Plane M, et al. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med. 1998;158:1238-1244.
26. Yarzebski J, Bujor CF, Goldberg RJ, et al. A community-wide survey of physician practices and attitudes toward cholesterol management in patients with recent acute myocardial infarction. Arch Intern Med. 2002;162:797-804.
27. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
28. Abookire SA, Karson AS, Bates DW. Use and monitoring of 'statin' lipid-lowering drugs compared with guidelines. Arch Intern Med. 2001;161:53-58.
29. Maviglia SM, Teich JM, Fiskio J, et al. Using an electronic medical record to identify opportunities to improve compliance with cholesterol guidelines. J Gen Intern Med. 2001;16:531-537.